CD274 and nonpapillary renal cell carcinoma: So far, angiogenesis inhibition with tyrosine kinase inhibitors (TKIs) combined with the inhibition of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 have revolutionized the treatment landscape of ccRCC patients with metastases [52,53].